Flavio Curnis Selected Research

NGR peptide

7/2022	Targeting the Blood-Brain Tumor Barrier with Tumor Necrosis Factor-α.
5/2016	NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors.
9/2012	Targeted drug delivery and penetration into solid tumors.
3/2012	Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy.
8/2011	Tumor vasculature targeting through NGR peptide-based drug delivery systems.
10/2008	The neovasculature homing motif NGR: more than meets the eye.
4/2006	Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif.
12/2002	Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Flavio Curnis Research Topics

Disease

48	Neoplasms (Cancer) 01/2024 - 02/2002
6	Lymphoma (Lymphomas) 07/2022 - 02/2002
5	Neuroblastoma 01/2019 - 07/2010
4	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2023 - 02/2002
4	Adenocarcinoma 01/2020 - 02/2002
3	Urinary Bladder Neoplasms (Bladder Cancer) 08/2023 - 01/2022
3	Melanoma (Melanoma, Malignant) 01/2023 - 02/2008
3	Prostatic Neoplasms (Prostate Cancer) 01/2023 - 01/2018
3	Parkinson Disease (Parkinson's Disease) 10/2021 - 11/2015
3	Fibrosarcoma 05/2021 - 05/2016
3	Disease Progression 01/2019 - 01/2016
2	Heart Failure 05/2007 - 03/2004
1	Leukemia 01/2024
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2023
1	Carcinoma (Carcinomatosis) 01/2023
1	Brain Neoplasms (Brain Tumor) 07/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2020
1	Experimental Melanoma 01/2018
1	Multiple Myeloma 01/2016
1	Alzheimer Disease (Alzheimer's Disease) 02/2014
1	Neurodegenerative Diseases (Neurodegenerative Disease) 02/2014
1	Vascular Tissue Neoplasms 12/2013
1	Malignant Mesothelioma 09/2012

Drug/Important Bio-Agent (IBA)

31	Peptides (Polypeptides)IBA 01/2023 - 02/2002
20	LigandsIBA 01/2024 - 01/2004
16	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2024 - 02/2002
14	IntegrinsIBA 08/2023 - 01/2004
13	Proteins (Proteins, Gene)FDA Link 01/2023 - 02/2002
13	CytokinesIBA 07/2022 - 08/2002
11	Chromogranin AIBA 01/2023 - 02/2002
10	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2021 - 08/2002
8	NGR peptideIBA 07/2022 - 12/2002
7	GoldIBA 08/2023 - 03/2013
6	AntibodiesIBA 01/2019 - 02/2002
6	Liposomes (Liposome)IBA 01/2019 - 04/2006
5	CD13 Antigens (Alanine Aminopeptidase)IBA 01/2024 - 01/2004
4	Cyclic PeptidesIBA 08/2023 - 12/2002
4	Glycine (Aminoacetic Acid)FDA LinkGeneric 09/2017 - 09/2008
4	Isoaspartic Acid (Isoaspartate)IBA 09/2017 - 09/2008
3	EnzymesIBA 01/2024 - 10/2008
3	Neuropilin-1IBA 11/2022 - 11/2018
3	Ceruloplasmin (Ferroxidase)IBA 10/2021 - 11/2015
3	human CNGRC fusion protein tumor necrosis factor-alphaIBA 11/2020 - 12/2013
3	Melphalan (Alkeran)FDA LinkGeneric 09/2011 - 01/2004
3	Arginine (L-Arginine)FDA Link 03/2010 - 09/2008
2	Antineoplastic Agents (Antineoplastics)IBA 01/2023 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 01/2023 - 02/2002
2	Interleukin-12 (IL 12)IBA 05/2021 - 11/2019
2	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 11/2015
2	AntigensIBA 01/2017 - 07/2010
2	Fibrinolysin FDA Link 01/2016 - 11/2002
2	Protein Isoforms (Isoforms)IBA 04/2006 - 02/2002
2	Complementary DNA (cDNA)IBA 10/2004 - 02/2002
1	Biotin (Vitamin H)FDA Link 01/2024
1	AvidinIBA 01/2024
1	polypeptide CIBA 01/2024
1	Contrast MediaIBA 08/2023
1	IRDye 800CWIBA 01/2023
1	Fluorescent Dyes (Fluorescent Probes)IBA 01/2023
1	ChromograninsIBA 11/2022
1	cysteinylglycine (Cys-Gly)IBA 07/2022
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2022
1	SaporinsIBA 01/2022
1	Prednisone (Sone)FDA LinkGeneric 11/2020
1	Vincristine (Oncovin)FDA LinkGeneric 11/2020
1	Rituximab (Mabthera)FDA Link 11/2020
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2020
1	Serine (L-Serine)FDA Link 10/2020
1	AcidsIBA 01/2019
1	Methotrexate (Mexate)FDA LinkGeneric 01/2019
1	Cytostatic AgentsIBA 01/2019
1	Evans Blue (Blue, Evans)FDA Link 11/2018
1	Coloring Agents (Dyes)IBA 11/2018
1	InterferonsIBA 01/2018
1	Monoclonal AntibodiesIBA 01/2018
1	succinimideIBA 01/2018
1	Immune Checkpoint InhibitorsIBA 01/2018
1	Therapeutic UsesIBA 01/2018
1	Granzymes (Granzyme)IBA 01/2018
1	asparagine-glycine-arginineIBA 09/2017
1	liposomal doxorubicin (Doxil)FDA Link 09/2017
1	H antigenIBA 01/2017
1	Minor Histocompatibility AntigensIBA 01/2017
1	Peptide Hydrolases (Proteases)FDA Link 11/2016
1	Plasminogen Activators (Plasminogen Activator)IBA 01/2016
1	IronIBA 11/2015
1	SuspensionsIBA 11/2015
1	AlbuminsIBA 03/2013
1	ChemokinesIBA 03/2012
1	Glutamyl Aminopeptidase (Aspartyl Aminopeptidase)IBA 07/2010
1	Tryptophan (L-Tryptophan)FDA Link 12/2008
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 12/2008

Therapy/Procedure

14	Therapeutics 01/2024 - 02/2002
6	Drug Therapy (Chemotherapy) 10/2020 - 08/2002
3	Immunotherapy 07/2022 - 03/2012
2	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2018 - 01/2017
1	Intravesical Administration 08/2023
1	Art Therapy 01/2022
1	Nanospheres 05/2021
1	Investigational Therapies (Experimental Therapy) 01/2019